Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Radiopharmaceutical growth is outpacing manufacturing infrastructure, says GlobalData

The rapid growth of radiopharmaceuticals is creating pressure on the manufacturing and supply infrastructure needed to support new diagnostic and cancer treatments. The global radiopharmaceutical market is estimated to be worth approximately $11 billion in 2026 and is projected to exceed $20 billion by 2030, says GlobalData, a leading intelligence and productivity platform. GlobalData’s monthly […]
Read more

Amyotrophic lateral sclerosis diagnosed prevalent cases to reach over 86,800 across 8MM in 2035, forecasts GlobalData

The burden of diagnosed prevalent cases of amyotrophic lateral sclerosis in the 8MM* is forecast to increase at an annual growth rate (AGR) of 0.71% from approximately 81,100 in 2025 to over 86,800 cases in 2035, according to GlobalData, a leading intelligence and productivity platform. GlobalData’s latest report, “Amyotrophic Lateral Sclerosis (ALS): Epidemiology Forecast to […]
Read more

Tirzepatide holds potential to outperform oral and injectable semaglutide for glycemic control and weight-loss in T2D, says GlobalData

Eli Lilly’s Mounjaro (tirzepatide) was more effective than both Novo Nordisk’s injectable Ozempic and oral Rybelsus (semaglutide) in helping adults with type 2 diabetes (T2D) achieve glycemic and weight-loss targets, according to real-world evidence presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026. The results highlight tirzepatide’s potential to address […]
Read more

Semaglutide dose escalation holds promise for cardiovascular edge over tirzepatide switch in T2D, says GlobalData

Adults with type 2 diabetes (T2D) who escalated their dose of Novo Nordisk’s Ozempic (semaglutide) experienced a lower observed risk of cardiovascular events than those who switched to Eli Lilly’s Mounjaro (tirzepatide), according to real-world cardiovascular outcomes data presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026. The results provide […]
Read more

Oral semaglutide holds potential as alternative to injectable GLP-1s for weight loss, says GlobalData

New real-world data from the OCTANE study shows that patients who were overweight or had obesity continued to lose weight after switching from Novo’s injectable Wegovy (semaglutide) or Lilly’s Zepbound (tirzepatide) to the oral semaglutide. The findings, presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026, support oral semaglutide as […]
Read more

Orforglipron holds potential as differentiated oral option for weight and glycemic control in T2D, says GlobalData

Data presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026 showed that Lilly’s Foundayo (orforglipron) was associated with greater reductions in both body weight and HbA1c than Novo’s Rybelsus (semaglutide) in adults with type 2 diabetes (T2D) who were overweight or had obesity. The results highlight orforglipron’s potential as a […]
Read more

Genentech’s approval in breast cancer among nine key value-driving biopharma catalysts in Q4 2026, reveals GlobalData

Several keenly anticipated approval decisions governing critical catalysts that can shape biopharma sentiment are expected in Q4 2024, alongside key clinical trial milestones that could influence the industry’s landscape. One of them is Genentech’s/Roche’s giredestrant, which faces two regulatory decisions in breast cancer; one is an  approval decision by November 30, for early-stage ER+/HER2- breast […]
Read more

GlobalData Healthcare to host webinar on China’s next frontier in biopharma dealmaking

China’s biopharma sector is moving from a sourcing option to a strategic priority for global pharma, with deal structures shifting from single-asset licensing to full platform acquisitions. To help healthcare and life sciences leaders navigate this shift, GlobalData Healthcare, the pharmaceutical and life sciences intelligence arm of GlobalData, a leading intelligence and productivity platform, will […]
Read more

China expands role in manufacturing new FDA-approved drugs, says GlobalData

Biopharma companies are increasingly choosing to manufacture their newer FDA-approved innovator and biosimilar products at facilities in China, signaling growing industry confidence in using the country as one of the bases for its manufacturing, according to GlobalData, a leading intelligence and productivity platform. Katia Djebbar, Pharma Analyst at GlobalData, comments: “The FDA-approved products currently being […]
Read more

South Korea’s dry eye market to see intensified competition with third homegrown drug approval, says GlobalData

South Korea’s Ministry of Food and Drug Safety has approved recoflavone (Latica/Recodu) for moderate to severe dry eye disease. Developed jointly by GL PharmaTech and Aju Pharmaceutical, recoflavone is the first domestically developed dry eye disease treatment approved in South Korea and the third prescription treatment authorized for the indication. The approval is expected to […]
Read more

CDMOs invest in European API capabilities to balance changing demand and supply chain risks, says GlobalData

Contract development and manufacturing organizations (CDMOs) are ramping up their active pharmaceutical ingredient (API) investments in Europe. A series of recent deals shows how companies are strengthening their infrastructure in the region, as they position themselves to develop and supply newer, more complex medicines, says GlobalData, a leading intelligence and productivity platform. GlobalData’s monthly Bio/Pharmaceutical […]
Read more

Classical Hodgkin lymphoma diagnosed incident cases to reach 28,000 across 8MM in 2035, forecasts GlobalData

The burden of diagnosed incident cases of classical Hodgkin lymphoma in the 8MM* is forecast to increase at an annual growth rate (AGR) of 0.31%, from 27,000 in 2025 to 28,000 cases in 2035, according to GlobalData, a leading intelligence and productivity platform. GlobalData’s latest report, “Hodgkin Lymphoma: Epidemiology Report and Forecast,” reveals that the […]
Read more

Lunsekimig results bolster Sanofi’s strategy to defend respiratory franchise ahead of Dupixent patent expiry, says GlobalData

Lunsekimig’s Phase IIb asthma data strengthen its case as a differentiated next-generation biologic, with dose-dependent reductions in exacerbations and improvements in lung function supporting progression into Phase III. The results could sharpen Sanofi’s strategy to defend its respiratory franchise ahead of Dupixent’s patent expiry, while intensifying competition in an increasingly crowded asthma biologics market, says […]
Read more

Tozorakimab results broaden biologic treatment across COPD population, says GlobalData

Tozorakimab’s (interleukin-33 (IL-33) inhibitor) Phase III chronic obstructive pulmonary disease (COPD) results strengthen the case for a new class of biologic treatment that could extend beyond eosinophil-defined patients. Consistent efficacy across OBERON and TITANIA trials, including those with low eosinophil counts, could broaden the addressable COPD population and intensify competition in a market where current […]
Read more

Mabwell’s 9MW1911 data support further testing of ST2 blockade in COPD, says GlobalData

At the European Respiratory Society (ERS) Congress 2026, Mabwell and collaborating investigators presented results from the company’s Phase Ib/IIa study in patients with chronic obstructive pulmonary disease (COPD). The randomized, double-blind, placebo-controlled trial evaluated the therapeutic efficacy and safety of 9MW1911, an anti-ST2 monoclonal antibody, in moderate-to-severe COPD. Although the efficacy findings were exploratory and […]
Read more
1 2 3 … 111